Bristol-Myers Squibb succession
Confirmation of Wayne Davidson as the top pharmaceutical officer in the combined businesses has rekindled interest in the post-Gelb management. Chairman Richard Gelb has set June 1993 as the target for his retirement. At that date, current Vice Chairman William Miller will be 64. Likely replacement will come from current triumverate of exec VPs: Davidson, Charles Heimbold and Michael Autera. Heimbold, 56, has responsibility for consumer products, the health care group (medical devices) and planning and development. Autera is chief financial officer and head of administration, a key post in a major merger period.
You may also be interested in...
Avadim Health argues National Advertising Division expects substantiation for its homeopathic topical claims at the same level FDA requires for NDAs. NAD also said although FTC’s competent, reliable scientific evidence standard is “flexible” to some degree, pain claims are held to a more rigid standard.
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.
The FDA has asked the company for more information to support its PoNS therapy for multiple sclerosis patients with gait deficit, including an additional analysis of clinical data and labeling modifications.